Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection

Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Makoto Nakamuta, Takeaki Satoh, Koichi Azuma, Akira Kawano, Yuichi Tanabe, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Elevated serum low-density lipoprotein cholesterol (LDL-C) level has been associated with sustained virological response (SVR) by chronic hepatitis C patients treated with pegylated-interferon (PEG-IFN) α and ribavirin (RBV). The aim of this study was to investigate the relation between the baseline LDL-C level and the treatment outcome from telaprevir (TVR)-based triple therapy. This prospective, multicenter study consisted of 241 treatment-experienced patients infected with HCV genotype 1b. All received 12 weeks of TVR in combination with 24 weeks of PEG-IFNα2b and RBV. The SVR rate was 81.3% (196 of 241) by intention-to-treat analysis. Higher LDL-C level was strongly associated with SVR (P = 1.3 × 10-8). The area under the receiver operating characteristic curve for predicting SVR was 0.78 and the cutoff value for the LDL-C level at baseline was 95 mg/dL. In multivariable logistic regression analysis of predictors of SVR, LDL-C ≥95 mg/dL (odds ratio [OR] 3.60, P = 0.0238), α-fetoprotein ≤5.0 ng/mL (OR 5.06, P = 0.0060), prior relapse to PEG-IFNα and RBV (OR 5.71, P = 0.0008), and rapid virological response (HCV RNA undetectable at week 4) (OR 5.52, P = 0.0010) were extracted as independent predictors of SVR. For prior partial and null responders, the SVR rates of the groups with LDL-C ≥95 mg/dL were significantly higher than those of the <95 mg/dL groups with IL28B TG/GG and pretreatment platelet count <150 × 109/L (both P < 0.05). The baseline LDL-C level exerted a potent influence on the SVR of treatment-experienced patients treated with TVR-based triple therapy, especially for prior partial and null responders to PEG-IFNα and RBV.

Original languageEnglish
Pages (from-to)102-109
Number of pages8
JournalAntiviral Research
Volume104
Issue number1
DOIs
Publication statusPublished - Apr 1 2014

Fingerprint

LDL Cholesterol
Genotype
Ribavirin
Infection
Odds Ratio
Interferons
Therapeutics
Fetal Proteins
Intention to Treat Analysis
Chronic Hepatitis C
telaprevir
Platelet Count
ROC Curve
HDL Cholesterol
Multicenter Studies
Logistic Models
Regression Analysis
Prospective Studies
RNA
Recurrence

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Virology

Cite this

Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection. / Ogawa, Eiichi; Furusyo, Norihiro; Kajiwara, Eiji; Nomura, Hideyuki; Dohmen, Kazufumi; Takahashi, Kazuhiro; Nakamuta, Makoto; Satoh, Takeaki; Azuma, Koichi; Kawano, Akira; Tanabe, Yuichi; Kotoh, Kazuhiro; Shimoda, Shinji; Hayashi, Jun.

In: Antiviral Research, Vol. 104, No. 1, 01.04.2014, p. 102-109.

Research output: Contribution to journalArticle

Ogawa, E, Furusyo, N, Kajiwara, E, Nomura, H, Dohmen, K, Takahashi, K, Nakamuta, M, Satoh, T, Azuma, K, Kawano, A, Tanabe, Y, Kotoh, K, Shimoda, S & Hayashi, J 2014, 'Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection', Antiviral Research, vol. 104, no. 1, pp. 102-109. https://doi.org/10.1016/j.antiviral.2014.01.004
Ogawa, Eiichi ; Furusyo, Norihiro ; Kajiwara, Eiji ; Nomura, Hideyuki ; Dohmen, Kazufumi ; Takahashi, Kazuhiro ; Nakamuta, Makoto ; Satoh, Takeaki ; Azuma, Koichi ; Kawano, Akira ; Tanabe, Yuichi ; Kotoh, Kazuhiro ; Shimoda, Shinji ; Hayashi, Jun. / Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection. In: Antiviral Research. 2014 ; Vol. 104, No. 1. pp. 102-109.
@article{3c08298e79ed4da0b6284989b48cae8d,
title = "Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection",
abstract = "Elevated serum low-density lipoprotein cholesterol (LDL-C) level has been associated with sustained virological response (SVR) by chronic hepatitis C patients treated with pegylated-interferon (PEG-IFN) α and ribavirin (RBV). The aim of this study was to investigate the relation between the baseline LDL-C level and the treatment outcome from telaprevir (TVR)-based triple therapy. This prospective, multicenter study consisted of 241 treatment-experienced patients infected with HCV genotype 1b. All received 12 weeks of TVR in combination with 24 weeks of PEG-IFNα2b and RBV. The SVR rate was 81.3{\%} (196 of 241) by intention-to-treat analysis. Higher LDL-C level was strongly associated with SVR (P = 1.3 × 10-8). The area under the receiver operating characteristic curve for predicting SVR was 0.78 and the cutoff value for the LDL-C level at baseline was 95 mg/dL. In multivariable logistic regression analysis of predictors of SVR, LDL-C ≥95 mg/dL (odds ratio [OR] 3.60, P = 0.0238), α-fetoprotein ≤5.0 ng/mL (OR 5.06, P = 0.0060), prior relapse to PEG-IFNα and RBV (OR 5.71, P = 0.0008), and rapid virological response (HCV RNA undetectable at week 4) (OR 5.52, P = 0.0010) were extracted as independent predictors of SVR. For prior partial and null responders, the SVR rates of the groups with LDL-C ≥95 mg/dL were significantly higher than those of the <95 mg/dL groups with IL28B TG/GG and pretreatment platelet count <150 × 109/L (both P < 0.05). The baseline LDL-C level exerted a potent influence on the SVR of treatment-experienced patients treated with TVR-based triple therapy, especially for prior partial and null responders to PEG-IFNα and RBV.",
author = "Eiichi Ogawa and Norihiro Furusyo and Eiji Kajiwara and Hideyuki Nomura and Kazufumi Dohmen and Kazuhiro Takahashi and Makoto Nakamuta and Takeaki Satoh and Koichi Azuma and Akira Kawano and Yuichi Tanabe and Kazuhiro Kotoh and Shinji Shimoda and Jun Hayashi",
year = "2014",
month = "4",
day = "1",
doi = "10.1016/j.antiviral.2014.01.004",
language = "English",
volume = "104",
pages = "102--109",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection

AU - Ogawa, Eiichi

AU - Furusyo, Norihiro

AU - Kajiwara, Eiji

AU - Nomura, Hideyuki

AU - Dohmen, Kazufumi

AU - Takahashi, Kazuhiro

AU - Nakamuta, Makoto

AU - Satoh, Takeaki

AU - Azuma, Koichi

AU - Kawano, Akira

AU - Tanabe, Yuichi

AU - Kotoh, Kazuhiro

AU - Shimoda, Shinji

AU - Hayashi, Jun

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Elevated serum low-density lipoprotein cholesterol (LDL-C) level has been associated with sustained virological response (SVR) by chronic hepatitis C patients treated with pegylated-interferon (PEG-IFN) α and ribavirin (RBV). The aim of this study was to investigate the relation between the baseline LDL-C level and the treatment outcome from telaprevir (TVR)-based triple therapy. This prospective, multicenter study consisted of 241 treatment-experienced patients infected with HCV genotype 1b. All received 12 weeks of TVR in combination with 24 weeks of PEG-IFNα2b and RBV. The SVR rate was 81.3% (196 of 241) by intention-to-treat analysis. Higher LDL-C level was strongly associated with SVR (P = 1.3 × 10-8). The area under the receiver operating characteristic curve for predicting SVR was 0.78 and the cutoff value for the LDL-C level at baseline was 95 mg/dL. In multivariable logistic regression analysis of predictors of SVR, LDL-C ≥95 mg/dL (odds ratio [OR] 3.60, P = 0.0238), α-fetoprotein ≤5.0 ng/mL (OR 5.06, P = 0.0060), prior relapse to PEG-IFNα and RBV (OR 5.71, P = 0.0008), and rapid virological response (HCV RNA undetectable at week 4) (OR 5.52, P = 0.0010) were extracted as independent predictors of SVR. For prior partial and null responders, the SVR rates of the groups with LDL-C ≥95 mg/dL were significantly higher than those of the <95 mg/dL groups with IL28B TG/GG and pretreatment platelet count <150 × 109/L (both P < 0.05). The baseline LDL-C level exerted a potent influence on the SVR of treatment-experienced patients treated with TVR-based triple therapy, especially for prior partial and null responders to PEG-IFNα and RBV.

AB - Elevated serum low-density lipoprotein cholesterol (LDL-C) level has been associated with sustained virological response (SVR) by chronic hepatitis C patients treated with pegylated-interferon (PEG-IFN) α and ribavirin (RBV). The aim of this study was to investigate the relation between the baseline LDL-C level and the treatment outcome from telaprevir (TVR)-based triple therapy. This prospective, multicenter study consisted of 241 treatment-experienced patients infected with HCV genotype 1b. All received 12 weeks of TVR in combination with 24 weeks of PEG-IFNα2b and RBV. The SVR rate was 81.3% (196 of 241) by intention-to-treat analysis. Higher LDL-C level was strongly associated with SVR (P = 1.3 × 10-8). The area under the receiver operating characteristic curve for predicting SVR was 0.78 and the cutoff value for the LDL-C level at baseline was 95 mg/dL. In multivariable logistic regression analysis of predictors of SVR, LDL-C ≥95 mg/dL (odds ratio [OR] 3.60, P = 0.0238), α-fetoprotein ≤5.0 ng/mL (OR 5.06, P = 0.0060), prior relapse to PEG-IFNα and RBV (OR 5.71, P = 0.0008), and rapid virological response (HCV RNA undetectable at week 4) (OR 5.52, P = 0.0010) were extracted as independent predictors of SVR. For prior partial and null responders, the SVR rates of the groups with LDL-C ≥95 mg/dL were significantly higher than those of the <95 mg/dL groups with IL28B TG/GG and pretreatment platelet count <150 × 109/L (both P < 0.05). The baseline LDL-C level exerted a potent influence on the SVR of treatment-experienced patients treated with TVR-based triple therapy, especially for prior partial and null responders to PEG-IFNα and RBV.

UR - http://www.scopus.com/inward/record.url?scp=84894284228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894284228&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2014.01.004

DO - 10.1016/j.antiviral.2014.01.004

M3 - Article

C2 - 24462955

AN - SCOPUS:84894284228

VL - 104

SP - 102

EP - 109

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 1

ER -